Addex Therapeutics Ltd
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-30 02:00 |
Regulatory News Service
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine …
|
English | 7.3 KB | |
| 2025-06-25 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 5.6 KB | |
| 2025-06-19 02:00 |
Regulatory News Service
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Upd…
|
English | 13.7 KB | |
| 2025-06-18 02:00 |
Report Publication Announcement
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Cal…
|
English | 5.9 KB | |
| 2025-06-06 02:00 |
Regulatory News Service
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…
|
English | 7.4 KB | |
| 2025-06-05 02:00 |
Regulatory News Service
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cou…
|
English | 6.4 KB | |
| 2025-06-03 02:00 |
General Meeting Notice
Addex Convenes Annual General Meeting 2025
|
English | 6.8 KB | |
| 2025-05-12 02:00 |
Regulatory News Service
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Suc…
|
English | 6.6 KB | |
| 2025-01-08 01:00 |
Regulatory News Service
Addex to Present at the 2025 Swiss Equities Baader Conference
|
English | 5.2 KB | |
| 2024-11-22 01:00 |
Regulatory News Service
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
English | 17.7 KB | |
| 2024-11-11 01:00 |
Earnings Release
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…
|
English | 7.1 KB | |
| 2024-09-30 02:00 |
Regulatory News Service
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results …
|
English | 17.2 KB | |
| 2024-09-19 02:00 |
Earnings Release
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net…
|
English | 7.0 KB | |
| 2024-09-04 02:00 |
Regulatory News Service
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Confe…
|
English | 5.2 KB | |
| 2024-08-27 02:00 |
Regulatory News Service
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Mo…
|
English | 7.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 | |
|
Antibiotice S.A. | Romania | ATB |